N-Acetyl-Selank: Acetylated Selank Variant Research Overview

N-Acetyl-Selank is a synthetic variant of Selank (TP-7) in which an acetyl group is added to the N-terminal alpha-amino group of the threonine residue. Selank itself is a synthetic heptapeptide anxiolytic derived from tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. For background on the parent compound, refer to the Selank research overview at /guides/selank-research-overview. This guide focuses specifically on the acetylated variant, while being transparent that the dedicated literature for N-Acetyl-Selank is extremely sparse — effectively absent from the indexed peer-reviewed scientific literature.

What Is N-Acetyl-Selank?

N-terminal acetylation is a common peptide modification used in pharmaceutical chemistry. Adding an acetyl group to the free alpha-amino group of the N-terminal residue removes the positive charge at that terminus, which can reduce the rate of aminopeptidase-catalyzed degradation — enzymes that cleave from the free amino terminus. The rationale for N-Acetyl-Selank is therefore primarily pharmacokinetic: the modification is intended to extend the already-brief half-life of the parent Selank (reported at approximately 1–2 minutes in plasma for the intact peptide before metabolite formation) by reducing N-terminal exopeptidase susceptibility. The sequence becomes Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro. No published pharmacokinetic comparison between Selank and N-Acetyl-Selank in animals or humans has been identified in the indexed peer-reviewed literature.

Presumed Mechanism of Action

In the absence of variant-specific mechanistic data, the pharmacological profile of N-Acetyl-Selank is generally assumed to resemble that of parent Selank: potential GABAergic modulation, BDNF upregulation, and enkephalin metabolism effects as described in the Selank literature (Volkova et al. 2016 Front Pharmacol; Semenova et al. 2010, 2017; Inozemtsev et al. 2019). Whether the acetyl group materially alters receptor binding affinity, CNS penetration, or downstream pharmacodynamic effects relative to Selank has not been studied in published work. These assumptions are standard working hypotheses in the research community but remain unvalidated for the acetylated variant specifically.

What the Research Shows (and Doesn't Show)

Transparency note: A systematic review of PubMed and PMC as of 2026 does not return peer-reviewed preclinical or clinical studies specifically investigating N-Acetyl-Selank. The compound is sold by research peptide vendors but lacks its own published research program. All available scientific literature on Selank's pharmacology pertains to the unmodified parent compound. This is a materially thinner evidence base than even Selank, which itself carries significant caveats about Russian-only research and absent Western replication.

The only substantive sources discussing N-Acetyl-Selank specifically are vendor product descriptions and review aggregator sites, none of which cite original research data for the acetylated variant. The compound is not registered as a pharmaceutical in any jurisdiction, including Russia. It is not approved by the FDA, EMA, MHRA, or TGA. Outside Russia, N-Acetyl-Selank is sold as a research peptide. Users and researchers interested in the compound should consider that claims about its specific effects relative to Selank are currently unsupported by published data.

Dose Ranges Referenced in Research Community Context

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

No published dose-finding studies exist for N-Acetyl-Selank in animals or humans. Doses circulated in the research community are typically extrapolated from unmodified Selank: subcutaneous doses in the range of 250–500 mcg have been discussed in analogy to Selank usage, but this extrapolation has no published validation for the acetylated form. These figures are not recommendations.

References

No primary research publications specific to N-Acetyl-Selank were identified. References below are for parent Selank, provided as the nearest available scientific context. For full Selank citations, see /guides/selank-research-overview.